The relationship between mutated genes of patients in the two groups was compared, showing significant co-mutation between MACF1 and PCLO in PRAD patients in the high-risk group (Figure 6E), and significant co-mutation between SPOP and ASH1L in PRAD patients in the low-risk group (Figure 6F). This evidence concerns the gene MACF1 and prostate adenocarcinoma.